13 Treatment groups Experimental Treatment Placebo Group Part A Randomized 1:1 Part B Sema, high dose trevo, and gareto followed by high dose trevo Randomized 1:1:1:1:1:1:1:1 Part B Sema, high dose trevo, and garetosmab (gareto) followed by SC placebo Randomized 1:1:1:1:1:1:1:1 Part B Sema, high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1 Part B Sema, high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1 Part B Sema, moderate-high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1 Part B Sema, moderate-high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1 Part B Sema and SC placebo and IV placebo followed by high dose trevogrumab (trevo) Randomized 1:1:1:1:1:1:1:1 Part B Semaglutide (sema) and subcutaneous (SC) placebo and intravenous (IV) placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1 Part C Sema and SC moderate dose trevo Randomized 1:2:2 Part C Sema and SC low dose trevo Randomized 1:2:2 Part C Sema and SC placebo Randomized 1:2:2 Part A Randomized 1:1 Find a Clinic Near You Who Is Running the Clinical Trial
The results are often dramatic, with many patients noticing a significant change in their leg contours
That mix of heavy demand, creative marketing and uneven oversight has been blamed for dosing blunders and quality problems that are not exactly confidence-inspiring
Regenerative Medicine of Iowa, PC
NAD+ production naturally declines with age
Quinicarn (L-Carnitine) is currently unavailable
